eTheRNA
eTheRNA BVBA is a spin-off company from VUB. The company was created in 2013 by Prof. Kris Thielemans out of the Laboratory of Molecular and Cellular Therapy (LMCT). eTheRNA is currently focused on the manufacturing of mRNA based drugs/vaccines to support clinical development and diagnostic applications. The aim is to grow into a Flanders based biopharma company that will develop a leadership position in not only mRNA manufacturing but also developing mRNA based drugs that enhance the immunological response against certain targeted diseases/indications.
1
Funding Rounds
$38.3m
Money raised
Overview
| Name | Phone | Social networks | |
|---|---|---|---|
| Kr** Th******** |
|
- |
Funding series
Funding Series Analysis
The company eTheRNA has raised a total of $38.3m in funding over 1 rounds.
Key Insights:
- eTheRNA Series B round, June 2020: $38.3m